NCT02081157CompletedNot Applicable
Use of GalaFlex in Ptotic Breast
C. R. Bard0 sites69 target enrollmentStarted: July 25, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 69
- Primary Endpoint
- The primary outcome for study success is defined as ptosis correction and maintenance of the surgical correction
Study Overview
Brief Summary
This study is to assess the physician preference in the clinical performance of the GalaFLEX mesh in soft tissue reinforcement during elective (cosmetic) plastic surgery to the breast, in particular the breast lift mastopexy and breast reduction procedures
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 21 Years to 99 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject is able to understand the risks and benefits of participating in the study and must be willing to sign and date the Informed Consent Form for this study approved by the Institutional Review Board (IRB.)
- •Be at least 21 years of age.
- •Be willing and able to comply with the requirements of the protocol.
- •Be willing to refrain from participating in any other investigational interventional study while enrolled in this study.
- •Female subjects must have a negative pregnancy test within the last 24 hours timeline and have no intentions of becoming pregnant during participation in the study, or be sterilized.
Exclusion Criteria
- •Subjects unwilling or unable to give written consent to participate in the investigation or unable to comply with the requirements of the protocol.
- •Subjects with known severe allergies manifested by a history of anaphylaxis or allergy to GalaFLEX mesh, poly-4-hydroxybutyrate (P4HB), a resorbable polymer, or silicone.
- •Subjects with known active infection and/or who received or are targeted to receive immunosuppressive therapy over the course of the study (such as rheumatoid arthritis).
- •Subjects who received any experimental drug or device within the previous three months.
- •Female subjects who were pregnant or lactating or were intending to become pregnant during the period of the study, or who would not use an adequate method of contraception (contraceptive pill, intra-uterine device) for the duration of the study.
- •Possessed any psychological condition, or was under treatment for any condition which, in the opinion of the Investigator and/or consulting physicians(s), would constitute an unwarranted risk.
- •Have collagen-vascular, connective disease, or bleeding disorders.
- •Have a BMI that is greater than or equal to
- •Have any disease, including uncontrolled diabetes, which is clinically known to impact wound healing ability.
- •Have an autoimmune disease, an immune deficiency, or is on immune suppression drugs.
- •Currently have an alcohol/substance abuse problem or have had a relapse within 1 year prior to screening visit.
- •Have concomitant unrelated condition of breast/chest wall/skin.
- •Have undergone previous breast surgery with the exception of breast biopsy.
- •Subject is currently a smoker or is a prior smoker who quit in the last 12 months.
- •Currently involved with claims for, or is accepting workers compensation.
- •Currently engaged in medical malpractice litigation.
Outcomes
Primary Outcomes
The primary outcome for study success is defined as ptosis correction and maintenance of the surgical correction
Time Frame: 1year
Correction of ptosis at 3 months must be Grade 0, Pseudoptosis, or Grade 1, and maintenance of ptosis correction at 12 months is demonstrated by a classification of ptosis Grade 1 or less
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Clinical Trial to Evaluate the Safety and Efficacy of Breast ImplantBreast CancerNCT01711710Seoul National University Hospital103
Completed
Not Applicable
Clinical Experience With a Tensor Fasciae Latae Perforator Flap Based on Septocutaneous PerforatorsSoft Tissue DefectNCT01136044Medical University of Graz14
Completed
Phase 3
Paclitaxel-coated Balloons in Femoral Indication to Defeat RestenosisPeripheral Artery DiseaseNCT01083030University Hospital, Saarland90
Completed
Not Applicable
Novel Endovascular Access Trial (NEAT)Chronic Kidney DiseaseNCT02036671C. R. Bard80
Completed
Not Applicable
Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall RadiotherapyBreast CancerNCT02544945Rob Rutledge16